Your browser doesn't support javascript.
COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum.
Wingard, John R; Ahn, Kwang Woo; Dandoy, Christopher; Perales, Miguel-Angel; Wood, William A; Logan, Brent; Riches, Marcie; Rizzo, J Douglas.
  • Wingard JR; Department of Medicine, University of Florida College of Medicine, Gainesville, Florida. Electronic address: wingajr@ufl.edu.
  • Ahn KW; Medical College of Wisconsin, Center for International Blood and Marrow Transplantation Research, Milwaukee Campus, Milwaukee, Wisconsin.
  • Dandoy C; Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.
  • Perales MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wood WA; Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Logan B; Medical College of Wisconsin, Center for International Blood and Marrow Transplantation Research, Milwaukee Campus, Milwaukee, Wisconsin.
  • Riches M; Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Rizzo JD; Medical College of Wisconsin, Center for International Blood and Marrow Transplantation Research, Milwaukee Campus, Milwaukee, Wisconsin.
Transplant Cell Ther ; 27(7): 533-539, 2021 07.
Article in English | MEDLINE | ID: covidwho-1240475
ABSTRACT
COVID-19 has significantly impacted the practice of hematopoietic cell transplantation (HCT) and likely affected outcomes of HCT recipients. Early reports document substantially higher case fatality rates for HCT recipients than seen in faced by the general population. Currently we do not have a clear picture of how much of this threat is present within the first year after HCT and how infection rates and outcomes vary with time after HCT. There are important because center-specific survival estimates for reporting purposes focus on 1-year post-HCT mortality. Transplantation centers have dramatically changed their practices in response to the pandemic. At many centers, quality assurance processes and procedures were disrupted, changes that likely affected team performance. Centers have been affected unevenly by the pandemic through time, location, and COVID-19 burdens. Assessment of center-specific survival depends on the ability to adjust for risk factors, such as COVID-19, that are outside center control using consistent methods so that team performance based on controllable risk factors can be ascertained. The Center for International Blood and Marrow Transplantation Research (CIBMTR) convened a working group for the 2020 Center Outcomes Forum to assess the impact of COVID-19 on both patient-specific risks and center-specific performance. This committee reviewed the factors at play and developed recommendations for a process to determine whether adjustments in the methodology to assess center-specific performance are needed.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Transplant Cell Ther Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Transplant Cell Ther Year: 2021 Document Type: Article